A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group.
Blauvelt A, et al.
Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25.
Br J Dermatol. 2021.
PMID: 32880909
Free PMC article.
Clinical Trial.
At week 24, ixekizumab was noninferior to guselkumab (50% vs. 52%, difference -2.3%), with no statistically significant difference in PASI 100 (P = 0.41). More patients receiving ixekizumab showed completely clear nails at week 24 (52% vs. 31%, P = 0.007). The median time …
At week 24, ixekizumab was noninferior to guselkumab (50% vs. 52%, difference -2.3%), with no statistically significant difference in PASI 1 …